Probe sought in Trump administration’s ouster of scientist

Politics

FILE – This Monday, April 6, 2020 file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. According to a study released on Tuesday, April 21, 2020, the malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in an analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers report. (AP Photo/John Locher)

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

WASHINGTON (AP) — Calls mounted Thursday for an investigation into the ouster of a senior government scientist who says he’s being punished for opposing widespread use of an unproven drug President Donald Trump touted as a remedy for COVID-19.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, says he was summarily removed from his job earlier this week and reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug favored by Trump.

On Thursday, House Energy and Commerce Committee Chairman Frank Pallone, D-N.J., joined in calling for an investigation by the Health and Human Services inspector general.

“Removing Dr. Bright in the midst of a pandemic would raise serious concerns under any circumstances, but his allegations that political considerations influenced this decision heighten those concerns and demand full accountability,” Pallone said. The inspector general’s office had no immediate response.

Bright is seeking to be reinstated as head of the research agency, said his lawyers Debra Katz and Lisa Banks. A performance review shows he received a top rating.

Controversy has swirled around hydroxychloroquine since Trump started promoting it from the podium in the White House briefing room.

BARDA, the agency that Bright formerly headed, is a unit of HHS created to counter threats from bioterrorism and infectious diseases. It has recently been trying to jump-start work on a vaccine for the coronavirus.

“I am speaking out because to combat this deadly virus, science — not politics or cronyism — has to lead the way,” Bright, who has a doctoral degree in immunology, said a statement released Wednesday by his lawyers.

“Specifically, and contrary to misguided directives, I limited the broad use of chloroquine and hydroxychloroquine, promoted by the administration as a panacea, but which clearly lack scientific merit,” Bright said.

“I also resisted efforts to fund potentially dangerous drugs promoted by those with political connections,” he added.

Asked about Bright at Wednesday’s briefing, Trump said he “never heard of him.”

“The guy says he was pushed out of a job,” Trump said. “Maybe he was. Maybe he wasn’t. … I don’t know who he is.”

Bright’s lawyers said Thursday they will soon file formal complaints with the HHS inspector general and the Office of Special Counsel, an independent agency that has as part of its charge the protection of government whistleblowers.

“While I am prepared to look at all options and to think ‘outside the box’ for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public,” Bright wrote in his statement.

He also alluded to “clashes with HHS political leadership” over his efforts to “invest early in vaccines and supplies critical to saving American lives.” One of the major criticisms of the Trump administration’s pandemic response is that little was done in the month of February to stockpile needed equipment.

“Science, in service to the health and safety of the American people, must always trump politics,” Bright said.

Trump has repeatedly touted the malaria drug during his regular coronavirus briefings, calling it a “game changer,” and suggesting its skeptics would be proved wrong. He has offered patient testimonials that the drug is a lifesaver.

But a recent study of 368 patients in U.S. veterans hospitals found no benefit from hydroxychloroquine — and more deaths. The study was an early look at the medication, which has prompted debate in the medical community, with many doctors leery of using it.

In a statement, HHS confirmed that Bright is no longer at the BARDA agency, but did not address his allegations of political interference in scientific matters.

HHS said it was Bright who had requested an emergency use authorization for chloroquine and hydroxychloroquine. For his part, Bright said he had insisted that the authorization be limited to a restricted group of patients, those hospitalized with confirmed COVID-19 under the supervision of a doctor.

Hydroxychloroquine was given to patients in the New York area, the nation’s most intense COVID-19 hot spot. It is usually administered in combination with the antibiotic azithromycin.

An official biography describes Bright as a flu and infectious-disease expert who joined the agency 10 years ago and was focused on vaccine development. He also held the title of HHS deputy assistant secretary for preparedness and response, reporting to Dr. Robert Kadlec.

Bright’s performance review shows he got the highest rating — “Level 5 – Achieved Outstanding Results” — in federal fiscal year 2019.

“Dr. Bright continues a very successful tenure in leading BARDA performing an essential (HHS) mission of developing and acquiring medical countermeasures for the Strategic National Stockpile,” wrote Kadlec, his boss, adding, “I have confidence” that Bright would meet future challenges facing the agency.

A copy of Bright’s performance review was provided to The Associated Press.

HHS said Bright is now assigned to the National Institutes of Health, working on new approaches to testing.

His allegations were first reported by The New York Times.

___

Associated Press writers Aamer Madhani, Deb Riechmann and Dustin Weaver contributed to this report.

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Trending Stories

Don't Miss

More Don't Miss